Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
58.9M
-
Number of holders
-
138
-
Total 13F shares, excl. options
-
47.9M
-
Shares change
-
-2.25M
-
Total reported value, excl. options
-
$197M
-
Value change
-
-$9.65M
-
Put/Call ratio
-
2.17
-
Number of buys
-
58
-
Number of sells
-
-91
-
Price
-
$4.11
Significant Holders of Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) as of Q1 2024
177 filings reported holding VNDA - Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share as of Q1 2024.
Vanda Pharmaceuticals Inc. - Common Stock, par value $0.001 per share (VNDA) has 138 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.9M shares
of 58.9M outstanding shares and own 81.44% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.14M shares), RENAISSANCE TECHNOLOGIES LLC (4.28M shares), VANGUARD GROUP INC (3.4M shares), ACADIAN ASSET MANAGEMENT LLC (2.37M shares), D. E. Shaw & Co., Inc. (1.8M shares), TANG CAPITAL MANAGEMENT LLC (1.75M shares), DIMENSIONAL FUND ADVISORS LP (1.72M shares), MORGAN STANLEY (1.51M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (1.42M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.25M shares).
This table shows the top 138 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.